Professor Thomas Powles
MBBS, MRCP, MD, Barts Cancer Institute presents Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) at the 2016 annual International Kidney Cancer Symposium.
Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC)
